| Literature DB >> 23885647 |
Eun Young Ki1, Seung Won Byun, Jong Sup Park, Sung Jong Lee, Soo Young Hur.
Abstract
Adenoma malignum (AM) of the cervix is a rare disease and it is difficult to diagnose due to the deceptively benign appearance of the tumor cells. These lesions have mucin-rich cystic lesions and are usually situated deep in the cervix. Since AM is very rare, standard screening tests, diagnostic tools and treatments have not yet been established. Radiologically, it mimics multiple nabothian cysts as a benign-looking tumor. Histologically, AM is a well-differentiated adenocarcinoma and could be misdiagnosed as a benign lesion. These findings make a preoperative diagnosis of AM difficult and can result in surgery being performed based on a misdiagnosis. We report here on four cases of pathologically confirmed AM.Entities:
Mesh:
Year: 2013 PMID: 23885647 PMCID: PMC3733704 DOI: 10.1186/1477-7819-11-168
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Figure 1Photomicrographs of large cysts showing the columnar epithelial lining. (a–d) Numerous irregularly shaped mucinous glands are seen, which are infiltrating below the surface of the endocervix (H&E stain, ×40, cases 1 to 4). (e–h) Diffusely infiltrating mucinous glands and well-formed glands are arranged irregularly, showing heterogeneity in size and shape. The glands show mild desmoplastic stromal reactions associated with lymphocytic infiltration (H&E stain, ×100, cases 1 to 4). (i–l) The differentiation of the glands is as good as that of normal endocervical glands (H&E stain, ×400, cases 1 to 4).
Figure 2Magnetic resonance imaging for case 2. (a,b) T2-weighted sagittal and axial images show multiple small cystic lesions with high signal intensity in the enlarged cervical stroma (narrow arrows). (c) A gadolinium-enhanced T1-weighted axial image shows multiple cystic lesions of unequal size. The abnormally enhanced area is the septum of the tumor (thick arrow).
Initial treatment and survival
| Lim | Type I RH (5/18) | None | |
| Type I RH + PLND (5/18) | None | Mean follow-up period: 49.2 months | |
| Type III RH + PLND (8/18) | CCRT (4/8) | Progression: 2/18 Death: 2/18 | |
| ERT (3/8) | | ||
| CTx (1/8) | | ||
| Ryuichi | RH | ERT + CTx | 5 years |
| | ERT + CTx | | |
| RH + omentectomy | ERT | 6 months | |
| RH | | 36 months | |
| Lymph node dissection | | 15 months | |
| Bulmer | RH + PLND | None | 3 years |
| Vaginal TH | ERT | 7 years | |
| Gotoh | TH | None | 2 years (NED) |
| Koo | RH | CTx | 12 months (NED) |
| Chang | None | ERT | 6 months (DOD) |
| RH | ERT + CTx | 46 month (DOD) | |
| TH | ERT + CTx | 18 months (DOD) | |
| RH | ERT | 5 years (NED) | |
| RH | ERT + CTx | 3 years (NED) | |
| Ki | TH + BA | None | 14 years (NED) |
| TH + BA | None | 6 years (NED) | |
| Type I RH + pelvic lymph node sampling | None | 33 months (NED) | |
| TH + PLND | None | 5 months (NED) |
BA: bilateral adnexectomy, CCRT: concurrent chemoradiation therapy, CTx: chemotherapy, DOD: died of the disease, ERT: external radiation, NED: no evidence of disease, PLND: pelvic lymph node dissection, RH: radical hysterectomy, TH: total hysterectomy.